Hear how Cambrian BioPharma is reinventing drug development (and pharmaceutical companies).
I’m excited to announce this australiabusinessblog.com Live event. The Cambrian BioPharma startup is developing a life-changing technology while pioneering a radical approach to a pharmaceutical company. Do not miss this australiabusinessblog.com Live takes place May 3 at noon PDT. Register here. It’s free to watch and participate.
Cambrian BioPharma bills itself as a new pharmaceutical company with a revolutionary approach to developing and managing drug development. James Peyer, PhD, co-founded the company in 2019 and has since raised more than $180 million to accelerate the development of drugs designed to target the causes of age-related diseases.
But that’s not the most interesting part. Peyer’s executive team has been successful in attracting top talent by giving them excess equity compared to traditional pharmaceutical companies. Instead of developing drugs within Cambrian BioPharma, the company essentially spins out the solution with the top scientists sitting in the C-suite alongside seasoned Cambrian BioPharma executives who will help run the new company.
Future Ventures’ Maryanna Saenko will also speak at this australiabusinessblog.com Live event. She is on the board of directors of Cambrian BioPharma and invested in the company’s Series A, B and C rounds. Together, the two will break down Cambrian BioPharma’s unique business model and explain why this process works so well.
Maryanna is also a co-founder and partner at Future Ventures, where she serves on the boards of several medical startups, including Deep Genomics, Earthshot Labs, and Gameto. She brings with her a wealth of knowledge and experience from her time at Future Ventures, and formerly Khosla Ventures, Threshold Ventures and DFJ. It is a pleasure to have her and James Peyer speak about the innovative work of Cambrian BioPharma.
